Activation of Interleukin-32 Pro-Inflammatory Pathway in Response to Influenza A Virus Infection by Li, Wei et al.
Activation of Interleukin-32 Pro-Inflammatory Pathway
in Response to Influenza A Virus Infection
Wei Li, Yan Liu, Muhammad Mahmood Mukhtar, Rui Gong, Ying Pan, Sahibzada T. Rasool, Yecheng Gao,
Lei Kang, Qian Hao, Guiqing Peng, Yanni Chen, Xin Chen, Jianguo Wu*, Ying Zhu*
State Key Laboratory of Virology, College of Life Sciences, Wuhan University, Wuhan, People’s Republic of China
Abstract
Background: Interleukin (IL)-32 is a recently described pro-inflammatory cytokine that has been reported to be induced by
bacteria treatment in culture cells. Little is known about IL-32 production by exogenous pathogens infection in human
individuals.
Methods and Findings: In this study, we found that IL-32 level was increased by 58.2% in the serum samples from a cohort
of 108 patients infected by influenza A virus comparing to that of 115 healthy individuals. Another pro-inflammatory factor
cyclooxygenase (COX)-2-associated prostaglandin E2 was also upregulated by 2.7-fold. Expression of IL-32 in influenza A
virus infected A549 human lung epithelial cells was blocked by either selective COX-2 inhibitor NS398 or Aspirin, a known
anti-inflammatory drug, indicating IL-32 was induced through COX-2 in the inflammatory cascade. Interestingly, we found
that COX-2-associate PGE2 production activated by influenza virus infection was significantly suppressed by over-expression
of IL-32 but increased by IL-32-specific siRNA, suggesting there was a feedback mechanism between IL-32 and COX-2.
Conclusions: IL-32 is induced by influenza A virus infection via COX-2 in the inflammatory cascade. Our results provide that
IL-32 is a potential target for anti-inflammatory medicine screening.
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Introduction
Influenza A virus (IV) is a highly contagious single-stranded RNA
virus that infects both the upper and lower respiratory tracts of
humans. The host innate immune Toll-like receptor 3 (TLR3) was
shown previously in cells of myeloid origin to recognize the viral
replicative, intermediate double-stranded RNA (dsRNA). Thus,
dsRNA is critical for the outcome of the infection and appears to be
an active component of viral infection that stimulates antiviral
activities.Itaccumulatesduring thereplicationofmanyviruses[1,2],
including influenza virus. Prominent sources of dsRNA include viral
RNAs containing double-stranded secondary structure and dsRNA
formed during viral replication [2]. Furthermore, TLR3 contributes
directly to the immune response of respiratory epithelial cells to
influenza A virus and dsRNA [3,4]. Therefore dsRNA treatment
was always used to mimic the viral infection in cell lines [5,6,7]. In
macrophages, dsRNA and viral infection stimulate the expression of
pro-inflammatory cytokines such as IL-1alpha, IL-1beta, tumor
necrosis factor, and IL-6 [1,8,9,10].
Cyclooxygenase (COX) is the rate-limiting enzyme in the
biosynthetic pathway of prostaglandins and thromboxanes. Prosta-
glandinsplayanimportantroleinmanybiologicalprocesses.Altered
prostanoid production is associated with a variety of illnesses,
including acute and chronic inflammation, cardiovascular disease
and colon cancer [11]. Two isoforms of COX were described:
COX-1 and COX-2.COX-1 is constitutively expressed inalmostall
tissues [12]; COX-2 is the inducible form of the enzyme, which is
expressed in response to inflammatory stimuli and growth factors
and is involved in mediating pain and inflammatory processes
[13,14]. In our previous studies, we identified two viral proteins, the
nucleoproteinand spike protein ofSARS-CoV,which were involved
in up-regulating COX-2 [15,16]. Prostaglandin E2 (PGE2)i s
synthesizedfromPGH2inavarietyofcells,whichitselfissynthesized
from arachidonic acid by the enzyme prostaglandin synthetase
COX-2. Its levels can be measured to access the COX-2 activity as
described in reference [5,6,17,18].
Interleukin-32 (IL-32), previously called natural killer cell
transcript 4, has been recognized as a pro-inflammatory cytokine
recently.It ismainlyexpressed innaturalkiller cells, T cells,epithelial
cells and blood monocytes. IL-32 can induce the pro-inflammatory
cytokines TNF-a and IL-1b in murine peritoneal macrophages as
well as in phorbol ester-differentiated human THP-1 cells [19]. It
plays an important role in innate and adaptive immune responses,
synergism between IL-32 and other well-characterized players in
innate immunity has recently been documented [20]. Furthermore,
IL-32 contributes to the synovitis during rheumatoid arthritis [21]. It
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NOD1 and NOD2 ligands to stimulate IL-1b and IL-6 release in a
caspase-1-dependent manner [23]. Recently Proteinase 3 has been
identified as a specific IL-32a binding protein which cleaves the
cytokine to enhance its activity [24].
A number of investigations demonstrated that viral infections
stimulate COX-2 expression, followed by PGE2 accumulation
[6,15,16,25,26]. However, the role of influenza A virus infection in
the regulation of the newly described pro-inflammatory factor IL-
32 expression is still unclear. Furthermore, since COX-2 and IL-
32 are obligatory mediators of inflammation, the question arises as
to whether there is an interaction between the two proteins or they
act as independent effectors of host inflammatory response to viral
infection.
Because COX-2 and IL-32 gene expression are associated with
inflammatory processes, the aim of this study is to investigate the
role of influenza A virus infection in the regulation of IL-32
expression and to determine the molecular mechanisms respon-
sible. Our results showed that influenza A virus infection or
poly(IC) treatment activates COX-2 and IL-32 expression by a
heretofore unrecognized mechanism, in which influenza A virus
stimulates IL-32 expression through COX-2, and IL-32 feedback
inhibits COX-2 expression.
Methods
Patients
The study examined 108 consecutive adults with influenza A
virus infection (59 male, 49 female, aged 39.2613.5 yr) seropos-
itive for influenza A antigen and 115 healthy adults (62 male, 53
female, aged 37.6611.3 yr) seronegative for influenza A antigen.
All adults were seronegative for markers of hepatitis B virus
(HBV), hepatitis C virus (HCV), hepatitis Delta virus, and HIV.
All of the investigated serum samples were obtained with the help
from Hubei provincial Center for Disease Control and Prevention
(Hubei CDC). Informed consent was obtained from each of the
patients. The collection of blood samples for research was
approved by the Institutional Review Board of the College of
Life Sciences, Wuhan University in accordance with guidelines for
the protection of human subjects.
Virus
The influenza virus strain A/chicken/Hubei/327/2004 (H5N1)
used in this study was provided by China Center for Type Culture
Collection (CCTCC). Stock virus was propagated in 10-day-old
embryonated chicken eggs for 36 to 48 h at 37uC. The allantoic
fluid was then harvested, and aliquots were stored at –80uC before
being used. The final concentration of H5N1 virus infection used
in this study was 1 multiplicity of infection (MOI).
Plasmids, antibodies, and inhibitors
pcDNA3.1-COX-2 was a gift from Dr. Kenneth K. Wu
(University of Texas-Houston Medical School, Houston, Texas,
USA). Luciferase reporter vector (pGL3) containing a COX-2
promoter region (2891/+9) was constructed previously [27]. IL-
32 promoter (2746/+25) was amplified from human genomic
DNA by PCR, using the following primers: 59-GTTACGCGT-
CCTATTTCAATATGACTGGT-39 (sense), 59- GTTAAGCT-
TAGGGAAAGTCCAGACTCGGG -39 (antisense); and then
inserted into pGL3-Basic vector to generate IL-32 promoter and
Luciferase gene fusion plasmid (pIL-32-Luc). An IL-32 construct
was created by RT-PCR amplification of the open reading frame
from A549 human lung epithelial cells. To create IL-32-encoding
vector, the IL-32 beta gene was amplified using the following
primers: 59- CATGAATTCCATGTGCTTCCCGAAGG -39
(sense), 59- CTACTCGAGGTATCTTCATTTTGAGGATTG
-39 (antisense); in which EcoRI and XhoI sites were introduced,
respectively. The PCR product was cloned into EcoRI and XhoI
sites of pCMV-tag2A (Stratagene) to generate plasmid Flag2A-IL-
32, in which IL-32 beta protein was tagged by FLAG.
All of the ten genes of influenza A virus H5N1 were obtained by
RT-PCR from H5N1 infected A549 cells and constructed into
pCMV-Flag2A vector to generate IV-gene expressing plasmids
(Flag2A-HA, Flag2A-NA, Flag2A-NP, Flag2A-NS1 Flag2A-NS2,
Flag2A-M1, Flag2A-M2, Flag2A-PA, Flag2A-PB1, Flag2A-PB2)
using specific pairs of primers for each influenza A virus gene as
follows: HA: 59- ACGGGATCCGATGGAGAAAATAGTGC-
TT -39 (sense), 59- ACGCTCGAGTGAACTCACAAATTTA -39
(antisense); NA: 59-GCGGAATTCTATGAATCCAAATCAGA-
AGATAATAAC-39 (sense), 59- AAAGGGCCCCTACTTGTCA-
ATGGTGAATGG -39 (antisense); NP: 59- AAAGGATCCCA-
TGGCGTCTCAAGGCACC -39 (sense), 59- ACCGAATTCT-
TAATTGTCATACTCC -39 (antisense); NS1: 59- ACAGGATC-
CGATGGATTCCAACACTGTGTC -39 (sense), 59- CTTGA-
ATTCTCAGCCACCTTATTTC -39 (antisense); NS2: 59- ACA-
GGATCCGATGGATTCCAACACTGTGTC -39 (sense), 59-
CTAGGGCCCATCATTAAATAAGCTGAAACGA -39 (anti-
sense); M1: 59- TCTGAATTCGATGAGTCTTCTAAC -39
(sense), 59- TTAGGGCCCGCAACAACAAGAGGATCACT -39
(antisense); M2: 59- TCTGAATTCGATGAGTCTTCTAAC -39
(sense), 59- TTTCTCGAGGGTAGTTTTTTACTCCAAT -39
(antisense); PA: 59- AATGGATCCTATGGAAGACTTTGTGC-
GAC -39 (sense), 59- CAGGGGCCCTACTTCAGTGCATGTG-
CGAG-39(antisense);PB1:59-CAAACGGATCCCATGGATGT-
CAATCCGAC -39 (sense), 59- CAAGAAGCTTTCACTATTTC-
TGCCGTCTG -39 (antisense); PB2; 59- GCAAAAGCAGGT-
CAAATATA -39 (sense), 59- GTTTTTAAACAATTCGACACTA
-39 (antisense); IL-32 siRNA plasmid was constructed by ligating the
corresponding pairs of oligonucleotide to pSilencer
TM 2.1-U6 neo
(Ambion, Inc., Augstin, TX, USA) based on the sequences described
previously [28]. All constructs was confirmed by DNA sequencing.
Monoclonal mouse antibody against human COX-2 was
purchased from Cayman Chemical Company (Ann Arbor, MI,
USA). Polyclonal goat antibody against human IL-32 was
purchased from R&D Systems, Inc. USA. Polyclonal goat
antibody specific for human b-actin (SC-1616) were purchased
from Santa Cruz Biotechnology, Inc (Santa Cruz, CA, USA).
N-(2-cyclohexylosy-4-nitrophenyl)-methanesulphonamide (NS398)
(Promega, Madison, WI) was dissolved in DMSO and used as
indicated concentrations according to reference [29]. Aspirin
(Sigma, St. Louis, MO, USA), Synthetic polyinosinic-polycy-
tidylic acid poly(IC) (Sigma, St. Louis, MO, USA), and
recombinant human interferon-c (IFN-c) (Peprotech, London,
UK) were dissolved in PBS and used at a final concentration of
5 mM, 50 mg/ml, 150 U/ml, respectively.
Cell culture
HEK 293T cells were cultured in DMEM (GibcoBRL, USA),
human lung epithelial cells A549 were cultured in F12K media
(GibcoBRL, USA), respectively. All media were supplemented
with 10% fetal calf serum, 100 U/ml penicillin and 100 mg/ml
streptomycin sulfate and all cell cultures were maintained at 37uC
in a 5% CO2 incubator.
Transient transfection and Luciferase reporter gene
assays
Cells were plated at density of 4.0610
5 cells per 24-well plate or
6-well plate and grown to confluence reaching about 80% at the
Influenza Virus Induces IL-32
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the pGL3-promoter plasmids, pRL-TK (Promega) were co-
transfected into the cells by using Lipofectamine 2000 reagent
(Invitrogen). If necessary, poly(IC), IFN-c, NS398, and Aspirin
were added into the culture media after transfection. 24 h post-
transfection, cells were serum-starved for another 24 h before
being harvested. Luciferase activities were measured 48 h after
transfection according to the manufacturer’s instructions (Pro-
mega) and Renilla Luciferase activities were determined as
internal control for transfection efficiency as previously described
[15]. Assays were performed in triplicate and expressed as
means6s.d. relative to vector or mock control as 100 (RLU) or
luciferase activity (LUC).
Semiquantitative RT-PCR analysis
Total RNA, isolated from A549 cells using Trizol reagent
(Invitrogen, Carlsbad, CA, USA), was treated with DNase I and
reverse-transcribed with MLV reverse transcriptase (Promega) and
random primers (Takara). PCR was performed in 25 mlr e a c t i o n s
with the detection primer pairs described as follows: IL-32 sense: 59-
CATGAATTCCATGTGCTTCCCGAAGG-39; IL-32 antisense:
59- CTACTCGAGGTATCTTCATTTTGAGGATTG -39.D e -
tection primers for COX-2, and b-actin were described previously
[15]. b-actin was amplified by PCR for normalization in all
Table 1. Demographic and baseline characteristics, serum
levels of PGE2 and IL-32 from influenza A positive patients and
healthy individuals.
Characteristic
Healthy
Individuals
(N=115)
Patients
(N=108) P Value
Age-yr 37.6611.3 39.2613.5 0.85
Male sex-no.(%) 62 (54) 59 (55) 0.91
Race or ethnic group-no.(%) Asian 115 (100) 108 (100) 1.00
Time-no.(%) 115 (100) 108 (100) 1.00
Oct.8th/2007-Oct.19th/2007
Region-no.(%) 115 (100) 108 (100) 1.00
Hubei province, China
HA-Antigen-positive-no.(%) 0 (0) 108 (100) ,0.001
Anti-HA-positive-no.(%) 0 (0) 108 (100) ,0.001
Viral genotype A (H3/H1)-no. 0 108 (85/23)
PGE2-pg/ml 299.5645.4 808.7652.9 ,0.001
IL-32-pg/ml 116.2629.3 183.8643.6 ,0.001
doi:10.1371/journal.pone.0001985.t001
Figure 1. COX-2 and IL-32 were induced in A549 human lung epithelial cells in response to influenza A virus infection or dsRNA
treatment in a time-dependent manner. Time-dependent of PGE2 (A) and IL-32 (B) accumulations in A549 culture supernatants are shown in
response to influenza A virus infection (1 MOI) or poly(IC) (50 mg/ml)+IFN-c (150 U/ml) treatment. Data are expressed as mean6s.d. of three
independent experiments. Time-dependent of COX-2 and IL-32 mRNA accumulations (C) in cell lysates are shown by Semiquantitative RT-PCR
analysis and protein productions (D) shown by western blot analysis, in which A549 cells were harvested at indicated time points after influenza A
virus infection (1 MOI) or 48 h treatment with poly(IC) (50 mg/ml)+IFN-c (150 U/ml). The gel or blot is a representative of three experiments with
similar results.
doi:10.1371/journal.pone.0001985.g001
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known isoforms of human IL-32. PCR products were analyzed by
electrophoresis on 1% agarose gel containing ethidium bromide.
Western blot analysis
Protein extracts of cultured cells were prepared by suspending
cells in lysis buffer (0.01% EDTA, 0.1% Triton X-100, 10%
proteinase inhibitors cocktail), sonication, and centrifugation.
Concentrations of proteins in supernatant were quantified using
protein assay kit (Bio-Rad). Western blot analysis was performed
using COX-2 and IL-32 antibodies and sample loading was
normalized by using b-actin antibody. Immunoblots were visualized
with the ECL detection system (Pierce, Rockford, IL, USA).
COX-2 activity
Because increased PGE2 is the metabolite of COX-2 enzyme
catalysis in epithelial cells, COX-2-derived PGE2 levels in the
culture medium was assayed by the Biotrak Prostaglandin E2
Enzyme Immunoassay system (R & D Systems) according to the
manufacturer’s protocol.
ELISA for IL-32 measurement
ELISA assays were developed using IL-32 antibody and a
polypeptide, H-KEELTPQKCSEPQSSK-OH, (GL Biochem Ltd.
Shanghai China) was synthesized as an antigen for making an IL-32
protein standard curve. ELISAs were prepared by coating the
bottom of a 96-well plate with diluted serum samples or culture
media. 50 mlo f2mg/ml capture antibody was incubated for one
hour then washed three times with TBST, followed by HRP-labeled
secondary antibody incubation for 15 minutes, and finally washed
six times with TBST. ELISAs were developed with TMB (Sigma)
substrate and the absorbance at double-wavelength 450 nm/
630 nm was measured. IL-32 concentrations were calculated from
the standard curve.
Statistical analysis
All experiments were reproducible and were carried out in
triplicate or quadruplicate. Each set of experiments was repeated at
least three times with similar results, and a representative one is
shown. The results are presented at the means6s.d. Student’s t test
for paired samples was used to determine statistical significance.
Differences were considered statistically significant at a value of
P#0.05.
Results
Serum levels of PGE2 and IL-32
The serum levels of PGE2 and IL-32 were significantly higher in
the cohort of patients with influenza A virus infection investigated
in comparison with healthy control individuals (mean6SEM for
PGE2, 808.7652.9 vs. 299.5645.4 pg/ml; for IL-32, 183.8643.6
Figure 2. Screening of viral proteins or viral replicative intermediate dsRNA involved in induction of COX-2/ IL-32. Reporter plasmids
pCOX-2-Luc (A), pIL-32-Luc (B), and pRL-TK were cotransfected along with all 10 viral gene constructs (Flag2A-HA, Flag2A-NA, Flag2A-NP, Flag2A-NS1,
Flag2A-NS2, Flag2A-M1, Flag2A-M2, Flag2A-PA, Flag2A-PB1, Flag2A-PB2) and control vectors (Flag2A) or treated with or without poly(IC) (50 mg/ml),
poly(IC) (50 mg/ml)+IFN-c (150 U/ml) into A549 cells which are indicated on the horizontal axis respectively. Luciferase activity was measured as
described in methods section. Results are expressed as the mean6s.d. of three independent experiments performed in triplicate and normalized by
Renilla activities.
doi:10.1371/journal.pone.0001985.g002
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described in Table 1.
COX-2 and IL-32 activation in response to influenza A
virus infection and dsRNA treatment in a time-dependent
manner
It has been reported that influenza virus can activate the
expression of COX-2 in cell culture systems [26] and that dsRNA
can induce the production of COX-2, followed by PGE2 release
[5]. Initially, we investigated whether influenza A virus infection
and dsRNA plays a role, if any, in the regulation of IL-32
expression. A549 cells were infected with influenza A virus or
treated with poly(IC)+IFN-c, results showed that A549 cells were
susceptible to influenza virus infection and apparent cytopathic
effect was observed after viral infection. The culture supernatants
and cell lysates were harvested at different time points after
infection or induction as follows: 0 h, 6 h, 12 h, 24 h, 48 h. PGE2
accumulation (Fig. 1A) and IL-32 production (Fig. 1B) in culture
supernatants were measured as described in materials and
methods section. COX-2, IL-32 mRNA (Fig. 1C) and protein
(Fig. 1D) expression levels in lysated cells were examined by
semiquantitative RT-PCR and western blot analyses, respectively.
These results suggested that both influenza A virus infection and
dsRNA treatment could activate the expression of COX-2 and IL-
32 in A549 cells in a time-dependent manner.
Identification of the viral components involved in
influenza A virus-stimulated COX-2 and IL-32 expression
To identify the viral components which play important roles in
IV-stimulated pro-inflammatory factors COX-2 and IL-32 expres-
sion, we screened all ten proteins of influenza virus: HA, NA, NP,
NS1, NS2, M1, M2, PA, PB1, PB2 and poly(IC) (to mimic viral
replicativeintermediate dsRNA)by luciferaseassays. Results showed
that poly(IC), poly(IC)+IFN-c, and NS1 are the most important
factors in the induction of either COX-2 (Fig. 2A) or IL-32 (Fig. 2B)
promoter activities, which means dsRNA and NS1 are the key viral
components involved in IV-triggered COX-2 and IL-32 expression
during viral infection. In this study, we focused on the function of
dsRNA in inflammatory response to IV infection.
DsRNA stimulates IL-32 through COX-2 pathway during
inflammatory response
To define the role of COX-2 in the regulation of influenza A
virus induced pro-inflammatory factor IL-32, poly(IC)+IFN-c
treatment was used to mimic the influenza A virus infection in
following experiments as reported previously[30].
Figure 3. DsRNA induces IL-32 is in COX-2-dependent manner. Reporter plasmid pIL-32-Luc (A), and pRL-TK were cotransfected along with
pcDNA3.1-COX-2 or pcDNA3.1 into A549 cells. Transfected cells by COX-2 plasmids were incubated for 12 h and then maintained for 36 h with
different final concentrations of NS398 as indicated, respectively. Luciferase activity was measured. Results are expressed as the mean6s.d. of three
independent experiments performed in triplicate and normalized by Renilla activities. A549 cells were transfected with different indicated amounts of
pcDNA3.1-COX-2 or pcDNA3.1. RT-PCR for IL-32 and b-actin (internal control) (B) in cell lysates, Elisa for IL-32 (C) in culture supernatants were
performed. (D) A549 cells were treated with poly(IC) (50 mg/ml)+IFN-c (150 U/ml) for 12 h and then different concentration of NS398 was added as
indicated for another 36 h. IL-32 and b-actin mRNA level were examined by RT-PCR. (E) A549 cells were stimulated by poly(IC) (50 mg/ml)+IFN-c
(150 U/ml) with or without 80 mM NS398 for 48 h. Time-dependent of IL-32 expression in culture supernatants were measured. The data represent
mean6s.d. of three separate experiments.
doi:10.1371/journal.pone.0001985.g003
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were determined. A549 cells were cotransfected with the reporter
plasmid pIL-32-Luc and pcDNA3.1, pcDNA3.1-COX-2 plus
different concentration of NS398 as mentioned in Fig. 3A,
pcDNA3.1 was used as empty vector control. Results from
Luciferase activity assay showed that the level of IL-32 promoter
activity was increased by COX-2 over-expression and it was
blocked by COX-2 inhibitor NS398 in a dose-dependent manner.
Secondly, to determine the effects of COX-2 on the activation
of IL-32 mRNA level and protein expression, A549 cells were
transfected with different amounts of pcDNA3.1-COX-2. Results
from RT-PCR using IL-32-specific, or b-actin-specific primers
showed that the levels of IL-32 mRNA were increased as the
amount of pcDNA3.1-COX-2 increased, but the levels of b-actin
mRNA remained relatively constant (Fig. 3B). Furthermore, IL-32
production in culture supernatants was stimulated by COX-2
over-expression in a dose-dependent manner (Fig. 3C).
Thirdly, results from RT-PCR analyses showed that the level of
IL-32 mRNA activated by poly(IC)+IFN-c was suppressed by
COX-2-specific inhibitor NS398 in a dose dependent manner
(Fig. 3D). Furthermore, IL-32 accumulation in culture superna-
tants stimulated by poly(IC)+IFN-c were suppressed by 80 mM
NS398 (Fig. 3E).
Taken together, these data suggest that COX-2 is an upstream
regulatory factor of dsRNA-triggered IL-32 production.
IL-32 feedback inhibits dsRNA-induced COX-2 expression.
The effect of IL-32 on the regulation of COX-2 promoter was
determined. A549 cells were cotransfected with the reporter plasmid
pCOX-2-Luc and pCMV-Flag2A, Flag2A-IL-32. Results from
Luciferase activity assay showed that the level of COX-2 promoter
activity was decreased by IL-32 over-expression (Fig. 4A).
To determine the effects of IL-32 on the regulation of COX-2
mRNA expression, PGE2 production, A549 cells were transfected
Figure 4. The feedback inhibition of IL-32 to dsRNA-induced COX-2 expression. Reporter plasmid pCOX-2-Luc (A) and pRL-TK were
cotransfected along with Flag2A-IL-32 or control vectors (Flag2A) into A549 cells. Luciferase activity was then measured 48 h post transfection. A549
cells were transfected with different amounts of Flag2A-IL-32 as indicated or Flag2A and stimulated by poly(IC) (50 mg/ml)+IFN-c (150 U/ml) for 48 h.
RT-PCR for COX-2 and b-actin (B) in lysated cells, measurement of PGE2 release (C) in culture supernatants were taken. Reporter plasmid pCOX-2-Luc
(D) and pRL-TK were cotransfected along with siRNA-IL-32 or siRNA-control into A549 cells and treated with poly(IC) (50 mg/ml)+IFN-c (150 U/ml) for
48 h. Luciferase activity was then measured. (E) A549 cells were transfected with siRNA-IL-32 or siRNA-control and stimulated by poly(IC) (50 mg/
ml)+IFN-c (150 U/ml) for 48 h. Time-dependent PGE2 release in culture supernatants was measured. The data represent mean6s.d. of three separate
experiments.
doi:10.1371/journal.pone.0001985.g004
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poly(IC)+IFN-c as the inducer. Results from RT-PCR using
COX-2-specific, or b-actin-specific primers showed that the levels
of COX-2 mRNA was decreased as the amount of Flag2A-IL-32
increased, but the levels of b-actin mRNA remained relatively
constant (Fig. 4B). Furthermore, PGE2 production in culture
supernatants was suppressed by IL-32 over-expression in a dose-
dependent manner (Fig. 4C).
To confirm the above results, IL-32-specific siRNA was
cotransfected along with reporter plasmid pCOX-2-Luc into A549
cells and treated with poly(IC)+IFN-c. Results from Luciferase
activity assay showed that the level of COX-2 promoter activity was
increased by knocking down IL-32 (Fig. 4D). Furthermore, PGE2
production in culture supernatants stimulated with poly(IC)+IFN-c
was enhanced by knocking down IL-32 (Fig. 4E).
Taken together, these data suggest that IL-32 plays a very
important role in the inflammatory response following an influenza
A/COX-2/IL-32 dependent positive regulatory order, while a
negative feedback to COX-2 biosynthesis was also first observed.
Influenza A-induced PGE2 production and IL-32
expression were inhibited by NS398 and Aspirin
To confirm the COX-2 and IL-32 regulatory loop, A549 cells
were infected by influenza A virus and treated with or without
selective COX-2 inhibitor NS398, or non-selective COX inhibitor
Aspirin, a widely used anti-inflammatory drug. Results showed
that IV-triggered PGE2 release (Fig. 5A) and IL-32 (Fig. 5B)
production in the culture supernatants were inhibited by either
NS398 or Aspirin, which indicated that IL-32 is an important pro-
inflammatory factor downstream of COX-2 during influenza A
virus infection.
Influenza A-induced PGE2 production was increased by
knocking down IL-32
The effect of IL-32 on the regulation of IV infection induced
PGE2 production was also determined. We found that PGE2
release in A549 cell culture supernatants stimulated by IV
infection was increased (Fig. 5C) and IL-32 production decreased
(Fig. 5D) by knocking down IL-32.
Taken together, these data demonstrate that a novel inflam-
matory pathway in response to influenza A virus infection and
dsRNA treatment was identified as described in Fig. 6.
Figure 5. Selective COX-2 inhibitor NS398 suppresses IL-32 expression and IL-32-specific siRNA upregulates COX-2 in influenza A
virus infected A549 cell. A549 cells were infected by influenza A virus (1 MOI) and treated with or without 80 mM NS398, 5 mM Aspirin for 48 h as
indicated on the horizontal axis. PGE2 release (A) and IL-32 production (B) in culture supernatants were measured. A549 cells were transfected with
siRNA-IL-32 or siRNA-control and infected by influenza A virus (1 MOI) for 48 h. PGE2 release (C) and IL-32 production (D) in culture supernatants were
measured. The data represent mean6s.d. of three separate experiments.
doi:10.1371/journal.pone.0001985.g005
Figure 6. A model for regulation of pro-inflammatory factors
COX-2 and IL-32 expression in response to influenza A virus
infection and double-stranded RNA
doi:10.1371/journal.pone.0001985.g006
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Our results demonstrate that significant increase of serum
COX-2-derived PGE2 and IL-32 levels were observed in influenza
A infected patients compared with healthy individuals. Viral
infection resulted in 2.7-fold increase in PGE2 synthesis and 58.2%
increase in IL-32 production. Both influenza A virus infection and
poly(IC)+IFN-c treatment in A549 human lung epithelial cells
were able to induce COX-2/ IL-32 mRNA and protein expression
as well as PGE2 and IL-32 accumulation in the cell culture
supernatants. IL-32 was induced by influenza virus infection
through COX-2-dependent mechanism.
Although pro-inflammatory factor COX-2 has been identified
as an obligatory mediator in the airway inflammation during
influenza virus infection [26], virtually little is currently known
regarding the regulation of a newly identified proinfammatory
factor IL-32 in influenza A virus infection or the mechanism
whereby influenza A virus upregulates IL-32 expression. The
present study provides considerable new information relevant to
these issues. We identified first a COX-2/IL-32 regulatory loop in
which COX-2 upregulated IL-32 expression and IL-32 feedback
inhibited COX-2 expression in influenza A virus infected A549
lung epithelial cells. At present, a possible ‘‘cross-talk’’ between
two important pro-inflammatory factors nitric oxide synthase
(NOS) and COX has been extensively examined in different cell
lines, tissues and under different pathophysiological conditions
with conflicting results [31]. But the relationship between COX-2
and IL-32 has not been evaluated.
Comparing the IV infection induced IL-32 level in cell culture
with that in human individuals, a significant difference between
them was observed, over 10-fold increase in cell culture versus
58.2% in human individuals. It is likely the pro-inflammatory
factor is not able to be increased sharply under physiological
conditions due to complex inflammation network in which pro-
inflammatory factors regulate each other.
Two viral components, the NS1 and viral replicative interme-
diate dsRNA were identified to be involved in IV infection
triggered COX-2 and IL-32 expression in A549 cells. Because
TLR3 contributes directly to the inflammatory response of
respiratory epithelial cells to both influenza A virus and dsRNA,
we focused on the function of dsRNA in the regulation of COX-2
and IL-32 expression in this study. Role of viral NS1 protein in the
pro-inflammatory process need further investigation.
Cyclooxygenase metabolizes arachidonic acid to prostaglandins
(PGs) and thromboxane [32]. COX-2 has been elucidated to be
crucial to the inflammatory response [33] and tumorigenesis
[34,35], so nonsteroidal anti-inflammatory drugs (NSAIDs)
selective for its inhibition are used clinically to treat inflammatory
arthropathies but always cause many side effects such as
gastrointestinal (GI) mucosa damage and cardiovascular adverse
events [36,37,38]. Aspirin is one of the classic NSAIDs, and its
anti-inflammatory activity is associated with cyclooxygenase
inhibition directly or indirectly [39]. NSAID-associated GI
mucosal injury is an important clinical problem and the increased
knowledge of physiological roles of COX-2 enzyme in a variety of
tissues, including stomach and kidney, together with the
withdrawal from the clinic trials of rofecoxib and valdecoxib
because of cardiovascular toxicity, have challenged the benefits of
selective COX-2 inhibition [38]. Our study identified a novel
COX-2 downstream pro-inflammatory factor IL-32 which could
be a potential target for screening anti-inflammatory drugs with
less adverse effects.
In summary, these studies provide new insights into a novel
model as described in Fig. 6 in which influenza A virus or
poly(IC)+IFN-c triggers pro-inflammatory factors COX-2 and IL-
32 expression, COX-2-derived PGE2 production, and subsequent
host inflammatory responses. In this model, we further demon-
strate that COX-2 is located up-stream of IL-32 in the positive
regulatory pathway. The cross-talk between the two genes is
described as follows: COX-2 upregulates IL-32 production, and
conversely, IL-32 attenuates COX-2 activity.
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